Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

Table 4 Association between biomarker changes and clinical response

Biomarker change	Clinical response rate (CR + PR)	P value
CEA
≥ 50% reduction	70.0%	< 0.05
< 50% reduction	40.0%
CA19-9
≥ 50% reduction	75.0%	< 0.05
< 50% reduction	42.9%
CA72-4
≥ 50% reduction	72.2%	< 0.05
< 50% reduction	38.5%
CD4+ /CD8+ ratio
≥ 1.5-fold increase	71.4%	< 0.05
< 1.5-fold increase	41.7%

CR: Complete response; PR: Partial response; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; CA72-4: Cancer antigen 72-4.